Madrigal Pharmaceuticals Newsroom

Oppenheimer Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $350

Futu NewsOct 23 20:31 · Ratings

Madrigal Pharmaceuticals (MDGL) Gets a Buy From Oppenheimer

TipRanksOct 23 19:56 · Ratings

Express News | Madrigal Pharmaceuticals Inc : Oppenheimer Cuts Target Price to $350 From $375

BreakingsOct 23 11:32

H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $390

Futu NewsOct 22 18:31 · Ratings

Madrigal Pharmaceuticals' Promising Outlook: Buy Rating for Rezdiffra Amidst Enthusiastic Trial Enrollment and Regulatory Milestones

TipRanksOct 22 18:25 · Ratings

Express News | Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients With Compensated Nash/Mash Cirrhosis

BreakingsOct 21 20:00

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients With Compensated NASH/MASH Cirrhosis

Madrigal PharmaceuticalsOct 21 12:00

Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?

Zacks Oct 18 21:00

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

GlobeNewswireOct 18 20:00

Cantor Fitzgerald Reiterates Neutral on Madrigal Pharmaceuticals

BenzingaOct 12 01:08

Madrigal Pharmaceuticals Analyst Ratings

BenzingaOct 12 01:07 · Ratings

Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Debt In A Risky Way?

Simply Wall StOct 11 20:32

Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $336

Futu NewsOct 8 19:31 · Ratings

Piper Sandler Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)

TipRanksOct 8 18:48 · Ratings

JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $415

Futu NewsOct 7 12:32 · Ratings

Buy Rating on Madrigal Pharmaceuticals: Rezdiffra's Rising Prescription Rates and Blockbuster Potential Drive Positive Outlook

TipRanksOct 7 12:25 · Ratings

Express News | Madrigal Pharmaceuticals Appoints DR. Michael R. Charlton as Senior Vice President, Clinical Development

BreakingsOct 1 20:00

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

GlobeNewswireOct 1 20:00

Madrigal Pharmaceuticals Announces Publication Of Health-Related Quality Of Life Results From The Phase 3 MAESTRO-NASH Trial Of Rezdiffra

BenzingaSep 30 20:03

Express News | Madrigal Pharmaceuticals Inc - Rezdiffra Achieves Primary Endpoints in Phase 3 Trial

BreakingsSep 30 20:00